Advertisement

Risks of recurrence of posttransplant lymphoproliferative disease, Hodgkin’s disease or Kaposi’s sarcoma after retransplantation

  • Israel Penn
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 29)

Abstract

Lymphomas and lymphoproliferations comprise 24% of posttransplant malignancies and Kaposi’s sarcoma (KS) 6%, if non-melanoma skin cancers and in situ carcinomas of the uterine cervix are excluded, as they are from most studies of patterns of malignancy [1]. A gratifying feature is that following treatment 41% of lymphomas and 36% of KS undergo complete remission. In some patients a complication of such therapy is loss of the allograft, which may necessitate retransplantation. A question that arises is whether retransplan-tation, with reinstitution of full dose immunosuppressive therapy will precipitate recurrence of the neoplasm. The current study examined the data accumulated by the Cincinnati Transplant Tumor Registry (CTTR) from the fall of 1968 till May 1997 to address this question.

Keywords

Autologous Bone Marrow Transplantation Smooth Muscle Tumor Kidney Allograft Renal Allograft Recipient Liver Allograft 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Penn I. Epidemiology of cancer in transplant patients. In: Touraine JL, Traeger J, Betuel H, Dubernard JM, Revillard JP, Dupuy C (eds.), Cancer in Transplantation, Prevention and Treatment. Dordrecht: Kluwer Academic Publishers, 1996: 3–15.Google Scholar
  2. 2.
    Penn I. Malignancy. Surg. Clin. N. Am. 1994; 74: 1247–1257.PubMedGoogle Scholar
  3. 3.
    Wu T-T, Swerdlow S, Locker J et al. Pathologic analysis of recurrent posttransplant lympho-proliferative disorders. Transplant. Proc. 1995; 27: 1193–1194.PubMedGoogle Scholar
  4. 4.
    Penn I. Sarcomas in organ allograft recipients. Transplantation 1995; 60: 1485–1491.PubMedGoogle Scholar
  5. 5.
    Hickey DP, Nalesnik MA, Vivas CA et al. Renal retransplantation in patients who lost their allografts during management of previous post-transplant lymphoproliferative disease. Clin. Transplant. 1990; 4: 187–190.Google Scholar
  6. 6.
    Peters M. Mechanisms of action of interferons (Review). Semin Liver Dis. 1989; 9: 235–239.PubMedCrossRefGoogle Scholar
  7. 7.
    Min AD. Does interferon precipitate rejection of liver allografts? (Editorial). Hepatology 1995; 22:1333–1335.PubMedGoogle Scholar
  8. 8.
    Penn I. Immunosuppression-a contributory factor in lymphoma formation. Clin. Transplant. 1992; 6: 214–219.Google Scholar
  9. 9.
    Doutrelepont JM, De Pauw L, Gruber SA et al. Renal transplantation exposes patients with previous Kaposi’s sarcoma to a high risk of recurrence. Transplantation 1996; 62: 463–466.PubMedCrossRefGoogle Scholar
  10. 10.
    Poch E, Oppenheimer F, Del Rio R et al. Reinstitution of immunosuppression in a renal transplant recipient after remission of Kaposi’s sarcoma. Transplantation 1992; 54: 162–163.PubMedCrossRefGoogle Scholar
  11. 11.
    Al-Sulaiman MH, Mousa DH, Dhar JM, Al-Khader AA. Does regressed posttransplantation Kaposi’s sarcoma recur following reintroduction of immunosuppression? Am. J. Nephrol. 1992; 12: 384–386.PubMedGoogle Scholar
  12. 12.
    Penn I. Effects of immunosuppression on preexisting cancers. Transplantation 1993; 55: 742–747.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Israel Penn

There are no affiliations available

Personalised recommendations